TCDA Tricida Inc

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close of market on Thursday, February 25, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its fourth quarter and year-end 2020 financial results and business progress. The call or webcast may be accessed as follows:

Tricida Fourth Quarter and Year-End 2020 Conference Call
Thursday, February 25, 2021 4:30 pm Eastern Time
	Webcast:	IR.Tricida.com
	Dial-in:	(800) 733-2954
	International:	(847) 413-3731
	Conference ID:	50111253

 

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact: Jackie CossmonTricida, Inc.Senior Vice President of Investor Relations and CommunicationsIR@Tricida.com

Source: Tricida, Inc.